Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ERIC A STROM and KELLY K HUNT.
ERIC A STROM
Connection Strength
1.717
KELLY K HUNT
  1. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol. 2015 Jan; 22(1):90-5.
    View in: PubMed
    Score: 0.129
  2. Radiation therapy as an adjuvant treatment after sentinel lymph node surgery for breast cancer. Surg Clin North Am. 2003 Aug; 83(4):911-30, x.
    View in: PubMed
    Score: 0.059
  3. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Feb 15; 97(4):926-33.
    View in: PubMed
    Score: 0.058
  4. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002 Nov 15; 95(10):2059-67.
    View in: PubMed
    Score: 0.057
  5. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol. 2002 Jul; 9(6):543-9.
    View in: PubMed
    Score: 0.055
  6. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol. 2002 Apr; 9(3):256-65.
    View in: PubMed
    Score: 0.054
  7. Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):671-8.
    View in: PubMed
    Score: 0.053
  8. Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys. 2021 10 01; 111(2):360-370.
    View in: PubMed
    Score: 0.051
  9. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001 Apr 15; 19(8):2240-6.
    View in: PubMed
    Score: 0.051
  10. Local-regional control in breast cancer patients with a possible genetic predisposition. Int J Radiat Oncol Biol Phys. 2000 Nov 01; 48(4):951-7.
    View in: PubMed
    Score: 0.049
  11. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000 Oct; 7(9):656-64.
    View in: PubMed
    Score: 0.049
  12. Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg. 2019 01; 269(1):150-157.
    View in: PubMed
    Score: 0.043
  13. Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer. Ann Surg Oncol. 1999 Jan-Feb; 6(1):102-8.
    View in: PubMed
    Score: 0.043
  14. Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. J Clin Oncol. 2018 Oct 31; JCO1800317.
    View in: PubMed
    Score: 0.043
  15. Feasibility of postmastectomy radiation therapy after TRAM flap breast reconstruction. Ann Surg Oncol. 1997 Jul-Aug; 4(5):377-84.
    View in: PubMed
    Score: 0.039
  16. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015 Oct; 1(7):931-41.
    View in: PubMed
    Score: 0.035
  17. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10.
    View in: PubMed
    Score: 0.034
  18. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
    View in: PubMed
    Score: 0.031
  19. Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: implications for targeting the undissected axilla. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):116-122.
    View in: PubMed
    Score: 0.030
  20. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7.
    View in: PubMed
    Score: 0.029
  21. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer. 2012 Oct 15; 118(20):4936-43.
    View in: PubMed
    Score: 0.027
  22. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):782-7.
    View in: PubMed
    Score: 0.026
  23. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
    View in: PubMed
    Score: 0.026
  24. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat. 2011 Jul; 128(2):421-7.
    View in: PubMed
    Score: 0.025
  25. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer. 2011 Apr 15; 117(8):1595-601.
    View in: PubMed
    Score: 0.025
  26. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010 Sep 01; 116(17):4000-6.
    View in: PubMed
    Score: 0.024
  27. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010 Aug 01; 77(5):1296-302.
    View in: PubMed
    Score: 0.024
  28. Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg. 2009 Oct; 209(4):425-433.e2.
    View in: PubMed
    Score: 0.023
  29. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):474-84.
    View in: PubMed
    Score: 0.021
  30. Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1022-7.
    View in: PubMed
    Score: 0.020
  31. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer. 2007 Dec 01; 110(11):2420-7.
    View in: PubMed
    Score: 0.020
  32. Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. Plast Reconstr Surg. 2007 Dec; 120(7):1755-1768.
    View in: PubMed
    Score: 0.020
  33. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1004-9.
    View in: PubMed
    Score: 0.019
  34. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):490-6.
    View in: PubMed
    Score: 0.019
  35. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol. 2006 Nov 01; 24(31):4971-5.
    View in: PubMed
    Score: 0.019
  36. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):352-7.
    View in: PubMed
    Score: 0.018
  37. Immediate breast reconstruction can impact postmastectomy irradiation. Am J Clin Oncol. 2005 Oct; 28(5):485-94.
    View in: PubMed
    Score: 0.017
  38. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 01; 23(25):5983-92.
    View in: PubMed
    Score: 0.017
  39. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):351-7.
    View in: PubMed
    Score: 0.017
  40. Breast conservation after neoadjuvant chemotherapy. Cancer. 2005 Feb 15; 103(4):689-95.
    View in: PubMed
    Score: 0.017
  41. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004 Dec 01; 22(23):4691-9.
    View in: PubMed
    Score: 0.016
  42. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42.
    View in: PubMed
    Score: 0.016
  43. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1074-9.
    View in: PubMed
    Score: 0.016
  44. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004 Jun 15; 22(12):2303-12.
    View in: PubMed
    Score: 0.016
  45. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):138-45.
    View in: PubMed
    Score: 0.016
  46. Delayed-immediate breast reconstruction. Plast Reconstr Surg. 2004 May; 113(6):1617-28.
    View in: PubMed
    Score: 0.016
  47. Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer. 2004 Feb 01; 100(3):490-8.
    View in: PubMed
    Score: 0.015
  48. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):336-44.
    View in: PubMed
    Score: 0.015
  49. Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):128-35.
    View in: PubMed
    Score: 0.015
  50. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol. 2003 Sep 01; 21(17):3244-8.
    View in: PubMed
    Score: 0.015
  51. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1225-33.
    View in: PubMed
    Score: 0.014
  52. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002 Jul 15; 53(4):880-8.
    View in: PubMed
    Score: 0.014
  53. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9.
    View in: PubMed
    Score: 0.014
  54. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002 Jan 01; 20(1):17-23.
    View in: PubMed
    Score: 0.013
  55. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82.
    View in: PubMed
    Score: 0.013
  56. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000 Jul 15; 47(5):1191-200.
    View in: PubMed
    Score: 0.012
  57. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000 Jul; 7(6):435-40.
    View in: PubMed
    Score: 0.012
  58. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol. 1999 Dec; 6(8):762-7.
    View in: PubMed
    Score: 0.012
  59. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7.
    View in: PubMed
    Score: 0.011
  60. Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am. 1999 May-Jun; 5(3):159-64.
    View in: PubMed
    Score: 0.011
  61. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am. 1998 Jul-Aug; 4(4):230-6.
    View in: PubMed
    Score: 0.010
  62. Role of conservation therapy for invasive lobular carcinoma of the breast. Ann Surg Oncol. 1997 Dec; 4(8):650-4.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.